Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $34,990,706 | $41,674,087 | $57,727,435 | $71,305,471 |
| - Cash | $13,523,933 | $13,693,591 | $16,241,313 | $10,308,157 |
| + Debt | $31,696,783 | $30,282,967 | $30,247,730 | $24,245,047 |
| Enterprise Value | $53,163,556 | $58,263,462 | $71,733,852 | $85,242,361 |
| Revenue | $41,067,196 | $41,399,540 | $43,951,547 | $39,005,087 |
| % Growth | -0.8% | -5.8% | 12.7% | – |
| Gross Profit | $19,701,622 | $19,804,231 | $20,781,856 | $18,776,817 |
| % Margin | 48% | 47.8% | 47.3% | 48.1% |
| EBITDA | $8,602,739 | $5,559,393 | $7,874,100 | $8,813,652 |
| % Margin | 20.9% | 13.4% | 17.9% | 22.6% |
| Net Income | $2,769,887 | $2,386,266 | $3,730,805 | $4,728,711 |
| % Margin | 6.7% | 5.8% | 8.5% | 12.1% |
| EPS Diluted | 1.04 | 0.89 | 1.43 | 1.85 |
| % Growth | 16.9% | -37.8% | -22.7% | – |
| Operating Cash Flow | $4,476,981 | $3,414,217 | $4,217,571 | $3,948,747 |
| Capital Expenditures | -$4,410,191 | -$5,336,705 | -$5,888,839 | -$4,972,587 |
| Free Cash Flow | $66,790 | -$1,922,488 | -$1,671,268 | -$1,023,840 |